Page last updated: 2024-09-03

almotriptan and ergotamine

almotriptan has been researched along with ergotamine in 5 studies

Compound Research Comparison

Studies
(almotriptan)
Trials
(almotriptan)
Recent Studies (post-2010)
(almotriptan)
Studies
(ergotamine)
Trials
(ergotamine)
Recent Studies (post-2010) (ergotamine)
18859422,352103103

Protein Interaction Comparison

ProteinTaxonomyalmotriptan (IC50)ergotamine (IC50)
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)0.056
Tyrosine-protein kinase LckHomo sapiens (human)6.499
Tyrosine-protein kinase FynHomo sapiens (human)3.16
Beta-2 adrenergic receptorHomo sapiens (human)2.761
Beta-1 adrenergic receptorHomo sapiens (human)4.142
Cytochrome P450 3A4Homo sapiens (human)1
Alpha-2A adrenergic receptorHomo sapiens (human)0.0021
D(2) dopamine receptorHomo sapiens (human)0.0043
Alpha-2B adrenergic receptorHomo sapiens (human)0.0038
Alpha-2C adrenergic receptorHomo sapiens (human)0.012
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)0.0008
D(1A) dopamine receptorHomo sapiens (human)1.728
Thromboxane-A synthase Homo sapiens (human)3.064
Alpha-1D adrenergic receptorHomo sapiens (human)0.049
5-hydroxytryptamine receptor 2AHomo sapiens (human)0.0065
5-hydroxytryptamine receptor 2CHomo sapiens (human)0.056
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)0.0008
D(3) dopamine receptorHomo sapiens (human)0.0043
5-hydroxytryptamine receptor 2BHomo sapiens (human)0.0035
5-hydroxytryptamine receptor 6Homo sapiens (human)0.002

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (80.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lombardo, F; Obach, RS; Waters, NJ1
Csiba, L; Ficzere, A1
Galván, J; Heras, J; Láinez, MJ; Vila, C1
Comas, A; Heras, J; Láinez, JM; Slof, J1
Autret-Leca, E; Beau-Salinas, F; Bensouda-Grimaldi, L; Cissoko, H; Jonville-Béra, AP1

Reviews

1 review(s) available for almotriptan and ergotamine

ArticleYear
[Treatment of migraine in patients with hypertension and ischemic heart disease].
    Ideggyogyaszati szemle, 2002, Jan-20, Volume: 55, Issue:1-2

    Topics: Adjuvants, Pharmaceutic; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Contraindications; Dihydroergotamine; Dopamine Agonists; Ergotamine; Humans; Hypertension; Indoles; Migraine Disorders; Myocardial Ischemia; Oxazolidinones; Retrospective Studies; Serotonin Receptor Agonists; Sumatriptan; Triazoles; Tryptamines; Vasoconstrictor Agents

2002

Trials

1 trial(s) available for almotriptan and ergotamine

ArticleYear
Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy.
    European journal of neurology, 2007, Volume: 14, Issue:3

    Topics: Acute Disease; Adult; Caffeine; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Ergotamine; Female; Humans; Male; Migraine Disorders; Nausea; Patient Satisfaction; Phosphodiesterase Inhibitors; Photophobia; Serotonin Receptor Agonists; Treatment Outcome; Tryptamines; Vasoconstrictor Agents

2007

Other Studies

3 other study(ies) available for almotriptan and ergotamine

ArticleYear
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
[Almotriptan vs. ergotamine plus caffeine for acute migraine treatment. A cost-efficacy analysis].
    Neurologia (Barcelona, Spain), 2009, Volume: 24, Issue:3

    Topics: Analgesics, Non-Narcotic; Caffeine; Cost-Benefit Analysis; Costs and Cost Analysis; Ergotamine; Health Care Costs; Humans; Migraine Disorders; Patient Satisfaction; Quality of Life; Treatment Outcome; Tryptamines

2009
Drug dependence associated with triptans and ergot derivatives: a case/non-case study.
    European journal of clinical pharmacology, 2010, Volume: 66, Issue:4

    Topics: Claviceps; Dihydroergotamine; Ergotamine; Humans; Migraine Disorders; Oxazolidinones; Piperidines; Pyrrolidines; Risk; Substance-Related Disorders; Sumatriptan; Tryptamines

2010